ALL Clinical Trial Landscape
Data updated: May 20, 2026
929 clinical trials tracked since 2008
Acute lymphoblastic leukemia (ALL) is a cancer of the blood and bone marrow that affects both children and adults, requiring continuous innovation in treatment strategies. The clinical trial landscape for ALL encompasses 920 registered trials since 2008, with 413 trials currently active, meaning they are recruiting, enrolling, or active but not recruiting. A significant portion of these active trials are in early phases, with 212 in Phase 1 and 245 in Phase 2, compared to 44 in Phase 3 and 10 in Phase 4. This distribution suggests a strong emphasis on early-stage investigation of novel therapies. Industry sponsorship is led by Novartis and Amgen, each with 5 active trials, followed by Chongqing Precision Biotech Co., Ltd with 4 active trials, Autolus Limited with 3 active trials, and Juventas Cell Therapy Ltd. with 2 active trials. The relatively high number of Phase 1 and 2 trials compared to Phase 3 and 4 trials suggests a focus on developing and testing new treatments for ALL.
418 active
/
929 total (since 2008)
216
Phase 1 Active
481 total
248
Phase 2 Active
526 total
46
Phase 3 Active
90 total
9
Phase 4 Active
25 total
Top Industry Sponsors
Sorted by active Active Done Failed
Novartis 5 8 6
Amgen 5 6 2
Chongqing Precision Biotech Co., Ltd 4 1 0
Autolus Limited 3 1 0
Juventas Cell Therapy Ltd. 2 1 1
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT04530565 ACTIVE NOT RECRUITING
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
National Cancer Institute (NCI) n=348
NCT05602194 ACTIVE NOT RECRUITING
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group n=440
NCT07570173 RECRUITING
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Merck Sharp & Dohme LLC n=340
NCT04994717 ACTIVE NOT RECRUITING
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
Amgen n=303
+ 85 more Phase 3 trials — see full database below
ALL — Trials Started by Year (last 10 years)
2016 44
2017 60
2018 46
2019 52
2020 46
2021 55
2022 60
2023 55
2024 72
2025 80
2026 45
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Novartis 19
Amgen 13
Chongqing Precision Biotech Co., Ltd 5
Autolus Limited 4
Juventas Cell Therapy Ltd. 4
Bellicum Pharmaceuticals 4
Merck 3
AstraZeneca 3
Hebei Senlang Biotechnology Inc., Ltd. 3
Ascentage Pharma Group Inc. 2
Active Trials by Phase
Phase 1 216
Phase 2 248
Phase 3 46
Phase 4 9
Enrollment Size Distribution
1-50 526
51-200 258
201-500 57
501-1k 17
1k+ 14
All Industry Sponsors
Sorted by active Active Done Failed
Novartis 5 8 6
Amgen 5 6 2
Chongqing Precision Biotech Co., Ltd 4 1 0
Autolus Limited 3 1 0
Juventas Cell Therapy Ltd. 2 1 1
Bellicum Pharmaceuticals 2 0 2
Merck 2 0 1
AstraZeneca 2 1 0
Hebei Senlang Biotechnology Inc., Ltd. 2 1 0
Ascentage Pharma Group Inc. 2 0 0
Pfizer 1 4 0
AbbVie 1 2 0
Kite, A Gilead Company 1 2 0
Fate Therapeutics 1 2 0
Wugen, Inc. 1 1 0
NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT04530565 ACTIVE NOT RECRUITING
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
National Cancer Institute (NCI) n=348
NCT05602194 ACTIVE NOT RECRUITING
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group n=440
NCT07570173 RECRUITING
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Merck Sharp & Dohme LLC n=340
NCT04994717 ACTIVE NOT RECRUITING
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
Amgen n=303
NCT03150693 RECRUITING
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology n=310
NCT03959085 RECRUITING
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group n=5,951
NCT02112916 ACTIVE NOT RECRUITING
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI) n=847
NCT02101853 ACTIVE NOT RECRUITING
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) n=669
NCT03914625 ACTIVE NOT RECRUITING
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI) n=6,720
NCT02883049 ACTIVE NOT RECRUITING
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
National Cancer Institute (NCI) n=5,949
NCT03007147 ACTIVE NOT RECRUITING
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group n=475
NCT02003222 ACTIVE NOT RECRUITING
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) n=488
NCT06051409 RECRUITING
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ascentage Pharma Group Inc. n=350
NCT04094311 RECRUITING
Study of Out of Specification for Tisagenlecleucel
Novartis Pharmaceuticals n=200
NCT05327894 RECRUITING
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Princess Maxima Center for Pediatric Oncology n=160
NCT01190930 ACTIVE NOT RECRUITING
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group n=9,350
NCT07223021 RECRUITING
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center n=130
NCT07502118 RECRUITING
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Health Institutes of Turkey n=40
NCT07223190 NOT YET RECRUITING
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Amgen n=560
NCT07441291 RECRUITING
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Peking University People's Hospital n=70
NCT06819592 RECRUITING
PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury
The George Institute n=3,300
NCT06860269 RECRUITING
A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
Assistance Publique - Hôpitaux de Paris n=1,200
NCT07366801 RECRUITING
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=64
NCT03020030 ACTIVE NOT RECRUITING
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute n=560
NCT07072585 NOT YET RECRUITING
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Children's Oncology Group n=1,708
NCT07297914 NOT YET RECRUITING
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Bambino Gesù Hospital and Research Institute n=1,000
NCT05457556 ACTIVE NOT RECRUITING
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Children's Oncology Group n=435
NCT03117751 ACTIVE NOT RECRUITING
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital n=790
NCT03589326 ACTIVE NOT RECRUITING
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda n=245
NCT07203352 RECRUITING
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
Nanfang Hospital, Southern Medical University n=154
NCT02716233 ACTIVE NOT RECRUITING
A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents
Assistance Publique - Hôpitaux de Paris n=2,044
NCT07152041 RECRUITING
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China n=150
NCT06882057 RECRUITING
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China n=3,000
NCT06855810 RECRUITING
Newly-diagnosed Pediatric T-cell ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China n=610
NCT07059156 RECRUITING
Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL
Shanxi Bethune Hospital n=50
NCT04851717 ACTIVE NOT RECRUITING
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
Acacia Pharma Ltd n=100
NCT03643276 RECRUITING
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Martin Schrappe n=5,000
NCT04314219 RECRUITING
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
King Faisal Specialist Hospital & Research Center n=264
NCT06361329 RECRUITING
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
First Affiliated Hospital of Zhejiang University n=81
NCT06764238 RECRUITING
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China n=1,800
NCT04722848 ACTIVE NOT RECRUITING
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
Gruppo Italiano Malattie EMatologiche dell'Adulto n=236
NCT06756152 RECRUITING
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=50
NCT06475820 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT05029531 RECRUITING
Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=80
NCT05515029 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=56
NCT01231412 COMPLETED
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center n=174
NCT01503632 COMPLETED
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Children's Oncology Group n=570
NCT02730299 COMPLETED
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd n=125
NCT04817761 TERMINATED
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Institut de Recherches Internationales Servier n=42
NCT02881086 COMPLETED
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University n=1,023
NCT03275636 COMPLETED
Haploidentical Donor vs mMUD in Hematological Malignancies
DKMS gemeinnützige GmbH n=98
NCT00557193 COMPLETED
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Children's Oncology Group n=218
NCT06179732 COMPLETED
Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities
The Mentor Initiative n=2,400
NCT02013167 TERMINATED
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Amgen n=405
NCT01802814 COMPLETED
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany n=700
NCT04145531 COMPLETED
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Jazz Pharmaceuticals n=229
NCT01951885 COMPLETED
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center n=101
NCT03476239 COMPLETED
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen n=121
NCT04095858 TERMINATED
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=11
NCT02999854 TERMINATED
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
Kiadis Pharma n=63
NCT02670252 COMPLETED
BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University n=550
NCT02566395 COMPLETED
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Northwell Health n=10
NCT02369653 COMPLETED
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Bristol-Myers Squibb n=512
NCT01518517 COMPLETED
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
ERYtech Pharma n=85
NCT01597778 COMPLETED
Double Cord Versus Haploidentical (BMT CTN 1101)
Medical College of Wisconsin n=368
NCT01439347 TERMINATED
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
Spectrum Pharmaceuticals, Inc n=26
NCT01817075 COMPLETED
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Children's Oncology Group n=177
NCT00671034 COMPLETED
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Children's Oncology Group n=166
NCT03066466 WITHDRAWN
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Loyola University
NCT01371656 COMPLETED
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Children's Oncology Group n=624
NCT03628053 WITHDRAWN
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
NCT01854567 COMPLETED
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Mesoblast, Ltd. n=49
NCT00720109 COMPLETED
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) n=63
NCT01305200 COMPLETED
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group n=226
NCT02042690 COMPLETED
Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
Peking University n=131
NCT01564784 COMPLETED
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Pfizer n=326
NCT01305655 COMPLETED
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Nordic Society for Pediatric Hematology and Oncology n=47
NCT01457040 COMPLETED
Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University n=200
NCT00929695 COMPLETED
Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
Fred Hutchinson Cancer Center n=164
NCT00819351 COMPLETED
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase
Rigshospitalet, Denmark n=650
NCT00816049 COMPLETED
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy
Rigshospitalet, Denmark n=775
NCT00944008 TERMINATED
PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia
PETHEMA Foundation n=7
NCT00795756 COMPLETED
Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia
Northern Italy Leukemia Group n=145
NCT01188798 COMPLETED
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital n=6
NCT00784017 COMPLETED
Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia
medac GmbH n=199
NCT00991744 SUSPENDED
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Nordic Society for Pediatric Hematology and Oncology n=100
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337
NCT01015261 COMPLETED
Allogenic Bone Marrow Transplantation (BMT) Compare With Cytoreduction and Chemotherapy in Acute Lymphoblastic Leukemia (ALL) Patients
Tehran University of Medical Sciences n=30
NCT07328503 RECRUITING
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT06124157 RECRUITING
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
NCT07387926 NOT YET RECRUITING
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals
NCT07584889 RECRUITING
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
Shenzhen University General Hospital
NCT03739814 RECRUITING
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT03504644 ACTIVE NOT RECRUITING
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
ECOG-ACRIN Cancer Research Group
NCT04067336 ACTIVE NOT RECRUITING
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
NCT06317662 RECRUITING
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
NCT06514794 RECRUITING
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
NCT06738368 RECRUITING
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
University of Washington
NCT06308588 RECRUITING
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03286634 ACTIVE NOT RECRUITING
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
National Hospital Organization Nagoya Medical Center
NCT05453500 ACTIVE NOT RECRUITING
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
University of Washington
NCT02506933 ACTIVE NOT RECRUITING
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT07109219 RECRUITING
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
AstraZeneca
NCT07575919 RECRUITING
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
Liping Dou
NCT07575971 RECRUITING
Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
Liping Dou
NCT07575412 NOT YET RECRUITING
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
The First Affiliated Hospital of Soochow University
NCT06481735 RECRUITING
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
NCT03984968 ACTIVE NOT RECRUITING
CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
NCT07301424 NOT YET RECRUITING
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
University of Alberta
NCT06773936 ENROLLING BY INVITATION
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
NCT07566377 RECRUITING
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
NCT05289687 RECRUITING
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
NCT07192237 NOT YET RECRUITING
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT07153796 ACTIVE NOT RECRUITING
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04726241 RECRUITING
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC
NCT05748171 RECRUITING
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
NCT07053059 RECRUITING
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
M.D. Anderson Cancer Center
NCT03821610 ACTIVE NOT RECRUITING
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
University of Birmingham
NCT02981628 RECRUITING
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
NCT07564453 RECRUITING
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
NCT06364423 RECRUITING
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
National Cancer Institute (NCI)
NCT03670966 RECRUITING
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT07562568 NOT YET RECRUITING
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
The First Affiliated Hospital of Soochow University
NCT06390319 RECRUITING
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
NCT06533748 RECRUITING
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
NCT04521231 RECRUITING
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
NCT07228741 RECRUITING
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
St. Jude Children's Research Hospital
NCT06287229 RECRUITING
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
M.D. Anderson Cancer Center
NCT07134088 ACTIVE NOT RECRUITING
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
NCT06816134 RECRUITING
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
The First Affiliated Hospital of Soochow University
NCT05761171 ACTIVE NOT RECRUITING
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
NCT03919240 RECRUITING
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
NCT05909059 RECRUITING
CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
NCT07313852 NOT YET RECRUITING
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT05519579 RECRUITING
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Northside Hospital, Inc.
NCT04544592 RECRUITING
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
NCT03960840 ACTIVE NOT RECRUITING
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis Pharmaceuticals
NCT03876769 ACTIVE NOT RECRUITING
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Novartis Pharmaceuticals
NCT07224100 RECRUITING
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
University of Washington
NCT03934372 RECRUITING
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Biosciences International Sàrl
NCT05456698 ACTIVE NOT RECRUITING
Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
NCT01424982 ACTIVE NOT RECRUITING
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT06839456 RECRUITING
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT03192397 ACTIVE NOT RECRUITING
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT02392572 RECRUITING
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT06395103 RECRUITING
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme LLC
NCT02143414 ACTIVE NOT RECRUITING
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT07523555 RECRUITING
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Beijing Biotech
NCT00792948 ACTIVE NOT RECRUITING
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT03849651 ACTIVE NOT RECRUITING
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT04404660 ACTIVE NOT RECRUITING
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Autolus Limited
NCT05303792 ACTIVE NOT RECRUITING
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Alliance for Clinical Trials in Oncology
NCT04329325 ACTIVE NOT RECRUITING
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT05735717 RECRUITING
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT06144606 RECRUITING
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
H. Lee Moffitt Cancer Center and Research Institute
NCT06533579 RECRUITING
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
NCT07493408 NOT YET RECRUITING
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
The University of Hong Kong
NCT06847269 RECRUITING
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
St. Jude Children's Research Hospital
NCT07400029 RECRUITING
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT06985485 RECRUITING
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
The First Affiliated Hospital of Soochow University
NCT05376111 RECRUITING
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
The First Affiliated Hospital of Soochow University
NCT04065399 RECRUITING
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Syndax Pharmaceuticals
NCT04904588 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT03590171 RECRUITING
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany
NCT06918431 RECRUITING
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
NCT06561074 RECRUITING
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
M.D. Anderson Cancer Center
NCT04644016 RECRUITING
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT07467733 NOT YET RECRUITING
Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy
Biocells Medical
NCT03970096 RECRUITING
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
NCT05442515 RECRUITING
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT06059391 RECRUITING
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT06316856 RECRUITING
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Beijing GoBroad Hospital
NCT04276870 RECRUITING
Orphan Indications for CD19 Redirected Autologous T Cells
Stephan Grupp MD PhD
NCT04128501 ACTIVE NOT RECRUITING
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
M.D. Anderson Cancer Center
NCT07443488 NOT YET RECRUITING
Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
NCT04195633 RECRUITING
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT06904482 RECRUITING
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Case Comprehensive Cancer Center
NCT03263572 RECRUITING
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT06052813 ACTIVE NOT RECRUITING
A Study of BN104 in the Treatment of Acute Leukemia
Institut de Recherches Internationales Servier (I.R.I.S.)
NCT05589896 RECRUITING
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
NCT03136146 RECRUITING
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
NCT03147612 ACTIVE NOT RECRUITING
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03441061 ACTIVE NOT RECRUITING
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
M.D. Anderson Cancer Center
NCT02861417 ACTIVE NOT RECRUITING
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT05579132 RECRUITING
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
MSD R&D (China) Co., Ltd.
NCT03938987 RECRUITING
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
University of Alberta
NCT05366218 RECRUITING
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
University Hospital Tuebingen
NCT06001385 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Center for International Blood and Marrow Transplant Research
NCT01574274 ACTIVE NOT RECRUITING
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
Dana-Farber Cancer Institute
NCT05460533 ACTIVE NOT RECRUITING
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Memorial Sloan Kettering Cancer Center
NCT04262843 ACTIVE NOT RECRUITING
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
NCT06054113 ACTIVE NOT RECRUITING
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Amgen
NCT03642626 ACTIVE NOT RECRUITING
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT06013423 RECRUITING
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT07356154 RECRUITING
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
NCT06648889 RECRUITING
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Goethe University
NCT03674411 ACTIVE NOT RECRUITING
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT05480449 RECRUITING
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Stephan Grupp MD PhD
NCT07301138 NOT YET RECRUITING
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
NCT03128034 RECRUITING
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT01371630 RECRUITING
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03622788 ACTIVE NOT RECRUITING
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT06253663 ACTIVE NOT RECRUITING
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Kite, A Gilead Company
NCT02553460 ACTIVE NOT RECRUITING
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
NCT06064903 RECRUITING
CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
Bambino Gesù Hospital and Research Institute
NCT04787263 ACTIVE NOT RECRUITING
CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
Bambino Gesù Hospital and Research Institute
NCT06316427 RECRUITING
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
Beijing GoBroad Hospital
NCT07070323 RECRUITING
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Beijing GoBroad Hospital
NCT07244406 RECRUITING
Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
Hebei Senlang Biotechnology Inc., Ltd.
NCT05940961 RECRUITING
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Sheng-Li Xue, MD
NCT03573700 ACTIVE NOT RECRUITING
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
NCT04060277 ACTIVE NOT RECRUITING
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT01885689 ACTIVE NOT RECRUITING
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
City of Hope Medical Center
NCT02877303 RECRUITING
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04148430 ACTIVE NOT RECRUITING
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
Memorial Sloan Kettering Cancer Center
NCT06128070 RECRUITING
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
City of Hope Medical Center
NCT03016377 ACTIVE NOT RECRUITING
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
NCT03779854 RECRUITING
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT07039877 RECRUITING
Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients
Hospital Universitario Dr. Jose E. Gonzalez
NCT07199855 ACTIVE NOT RECRUITING
Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
Zhejiang University
NCT05192889 ACTIVE NOT RECRUITING
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
NCT04975555 ACTIVE NOT RECRUITING
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
NCT06704152 RECRUITING
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
BlueSphere Bio, Inc
NCT07175415 NOT YET RECRUITING
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT05745714 RECRUITING
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT05658640 RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT05751044 RECRUITING
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT04546399 RECRUITING
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
NCT04150497 RECRUITING
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
NCT05884333 RECRUITING
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT03399773 ACTIVE NOT RECRUITING
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT04315324 RECRUITING
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
SWOG Cancer Research Network
NCT03765177 RECRUITING
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Ottawa Hospital Research Institute
NCT02790515 ACTIVE NOT RECRUITING
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT05667506 RECRUITING
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Juventas Cell Therapy Ltd.
NCT04684147 RECRUITING
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
NCT03628612 ENROLLING BY INVITATION
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Autolus Limited
NCT06213636 RECRUITING
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Essen Biotech
NCT05182385 ACTIVE NOT RECRUITING
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Goethe University
NCT07079696 NOT YET RECRUITING
Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT02094794 ACTIVE NOT RECRUITING
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
City of Hope Medical Center
NCT07072494 RECRUITING
CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
Zhujiang Hospital
NCT06220097 ACTIVE NOT RECRUITING
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT03739502 RECRUITING
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT05805605 RECRUITING
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT06815003 RECRUITING
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
NCT07008885 RECRUITING
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
NCT03314974 RECRUITING
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT03817320 ACTIVE NOT RECRUITING
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
NCT06703216 NOT YET RECRUITING
Pre-emptive Anakinra for Cytokine Event Reduction
Ann & Robert H Lurie Children's Hospital of Chicago
NCT05800210 RECRUITING
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT07021677 RECRUITING
Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"
Tata Memorial Centre
NCT07012447 RECRUITING
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
yuejun Liu
NCT06184009 RECRUITING
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Jae Wook Lee
NCT06257394 RECRUITING
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Hyoung Jin Kang
NCT03104491 RECRUITING
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Leland Metheny
NCT05470777 RECRUITING
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
The First Affiliated Hospital of Soochow University
NCT03512405 ACTIVE NOT RECRUITING
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
City of Hope Medical Center
NCT05364762 ACTIVE NOT RECRUITING
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
NCT06718244 RECRUITING
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Ruijin Hospital
NCT03114865 ACTIVE NOT RECRUITING
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06034561 RECRUITING
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Instituto do Cancer do Estado de São Paulo
NCT06686108 RECRUITING
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT02646839 ENROLLING BY INVITATION
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Michael Pulsipher
NCT03509961 RECRUITING
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Pediatric Transplantation & Cellular Therapy Consortium
NCT06061094 RECRUITING
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
Goethe University
NCT04920968 RECRUITING
Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"
Maria Sklodowska-Curie National Research Institute of Oncology
NCT04232241 ACTIVE NOT RECRUITING
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
Universitätsklinikum Hamburg-Eppendorf
NCT06911710 RECRUITING
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Tianjin Medical University General Hospital
NCT04233346 ACTIVE NOT RECRUITING
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Otsuka Beijing Research Institute
NCT06886074 RECRUITING
Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Hospital Universitario Dr. Jose E. Gonzalez
NCT04781634 RECRUITING
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
Chongqing Precision Biotech Co., Ltd
NCT06299462 RECRUITING
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
NCT06559345 RECRUITING
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
The First Affiliated Hospital of Zhengzhou University
NCT06557161 RECRUITING
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
The First Affiliated Hospital of Zhengzhou University
NCT06564545 RECRUITING
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
The First Affiliated Hospital of Zhengzhou University
NCT06564493 RECRUITING
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
The First Affiliated Hospital of Zhengzhou University
NCT06777264 NOT YET RECRUITING
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1
First Affiliated Hospital of Zhejiang University
NCT06179524 RECRUITING
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Beijing Yongtai Ruike Biotechnology Company Ltd
NCT05281809 RECRUITING
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister
NCT06754267 RECRUITING
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
First Affiliated Hospital of Zhejiang University
NCT06742515 RECRUITING
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
First Affiliated Hospital of Zhejiang University
NCT06393985 RECRUITING
Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
The First Affiliated Hospital of Soochow University
NCT06420076 RECRUITING
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Essen Biotech
NCT06608732 RECRUITING
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Institute of Hematology & Blood Diseases Hospital, China
NCT06658925 NOT YET RECRUITING
Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL
Institute of Hematology & Blood Diseases Hospital, China
NCT04475731 ACTIVE NOT RECRUITING
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT06635330 RECRUITING
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Kara Yakhteh Tajhiz Azma Company
NCT06631040 NOT YET RECRUITING
Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL
Shahid Beheshti University of Medical Sciences
NCT06608342 RECRUITING
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT03541083 ACTIVE NOT RECRUITING
Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT05334823 RECRUITING
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Chongqing Precision Biotech Co., Ltd
NCT06508099 RECRUITING
Vitamin A and D Supplementation in Allogeneic HCT
St. Petersburg State Pavlov Medical University
NCT03676504 RECRUITING
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
University Hospital Heidelberg
NCT06477549 RECRUITING
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
St. Petersburg State Pavlov Medical University
NCT02061800 ACTIVE NOT RECRUITING
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Diane George
NCT05310591 RECRUITING
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Assistance Publique - Hôpitaux de Paris
NCT06206174 RECRUITING
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx Co., Ltd.
NCT06247501 RECRUITING
Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation
Seoul National University Hospital
NCT06220487 RECRUITING
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Nanfang Hospital, Southern Medical University
NCT05082519 RECRUITING
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Etan Orgel
NCT06081478 RECRUITING
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Beijing Tongren Hospital
NCT06082934 RECRUITING
Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia
Xijing Hospital
NCT05931757 NOT YET RECRUITING
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
The First Affiliated Hospital of Soochow University
NCT05648019 RECRUITING
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
KK Women's and Children's Hospital
NCT04499573 ACTIVE NOT RECRUITING
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NCT01744223 ACTIVE NOT RECRUITING
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
NCT03301168 ACTIVE NOT RECRUITING
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
NCT05054465 NOT YET RECRUITING
A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
Israeli Medical Association
NCT04746209 RECRUITING
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Medical College of Wisconsin
NCT03709719 ACTIVE NOT RECRUITING
Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia
Assistance Publique - Hôpitaux de Paris
NCT06570915 WITHDRAWN
Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
NCT03808610 TERMINATED
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT05268003 TERMINATED
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03856216 TERMINATED
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
NCT01384513 COMPLETED
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02625480 COMPLETED
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Kite, A Gilead Company
NCT02997761 COMPLETED
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
University of California, Davis
NCT04747912 SUSPENDED
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
NCT05909527 WITHDRAWN
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
NCT03913559 TERMINATED
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
NCT06705530 COMPLETED
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
National Research Center for Hematology, Russia
NCT05466994 COMPLETED
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)
M.D. Anderson Cancer Center
NCT03698552 TERMINATED
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04191187 COMPLETED
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT02328014 COMPLETED
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Acerta Pharma BV
NCT03160079 COMPLETED
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
University of California, San Diego
NCT04035434 TERMINATED
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics AG
NCT03480438 COMPLETED
Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab
Goethe University
NCT04501614 TERMINATED
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Takeda
NCT02458014 COMPLETED
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
M.D. Anderson Cancer Center
NCT03860844 TERMINATED
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Sanofi
NCT03564678 TERMINATED
Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT01660607 COMPLETED
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Stanford University
NCT05032183 TERMINATED
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT06009107 WITHDRAWN
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
Juventas Cell Therapy Ltd.
NCT02793544 COMPLETED
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT03333486 TERMINATED
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
NCT02722668 COMPLETED
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT00674479 COMPLETED
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT02420717 TERMINATED
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03792633 COMPLETED
Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL
University of Pennsylvania
NCT02220985 COMPLETED
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
NCT03246906 TERMINATED
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT05594784 COMPLETED
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
NCT04752163 TERMINATED
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04340167 COMPLETED
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children
Beijing Boren Hospital
NCT04325841 COMPLETED
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
Beijing Boren Hospital
NCT01350245 COMPLETED
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03576547 TERMINATED
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT01532635 TERMINATED
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03434730 COMPLETED
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
NCT06865352 COMPLETED
Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation
Fondazione IRCCS Policlinico San Matteo di Pavia
NCT02484430 COMPLETED
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT02396134 COMPLETED
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT02828358 COMPLETED
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
NCT03373071 COMPLETED
Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
Bambino Gesù Hospital and Research Institute
NCT04083170 TERMINATED
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
NCT04029688 TERMINATED
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
NCT03575325 COMPLETED
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
NCT04340154 TERMINATED
Study of Sequential CAR-T Cell Treating Leukemia Children
Beijing Boren Hospital
NCT01266083 COMPLETED
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
NCT02614066 COMPLETED
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Kite, A Gilead Company
NCT04762875 TERMINATED
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Ensoma
NCT04788472 COMPLETED
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
Zhejiang University
NCT04151706 COMPLETED
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Robert Lowsky
NCT05557110 COMPLETED
Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL
Chen Suning
NCT04554459 TERMINATED
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
Institute of Hematology and Blood Transfusion, Czech Republic
NCT03488225 TERMINATED
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT01134575 COMPLETED
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
NCT05936229 WITHDRAWN
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
NCT03088709 TERMINATED
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
NCT04969601 COMPLETED
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
Assistance Publique - Hôpitaux de Paris
NCT05740449 WITHDRAWN
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT02199184 COMPLETED
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT02000427 COMPLETED
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Amgen
NCT06210750 WITHDRAWN
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
NCT05895201 WITHDRAWN
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
NCT05433532 COMPLETED
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The First Affiliated Hospital of Soochow University
NCT02340884 COMPLETED
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Seattle Children's Hospital
NCT04554485 COMPLETED
Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)
Institute of Hematology and Blood Transfusion, Czech Republic
NCT03056339 COMPLETED
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT05613348 WITHDRAWN
CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
Zhujiang Hospital
NCT03267030 COMPLETED
Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase
Birgitte Klug Albertsen
NCT03982992 WITHDRAWN
Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
Ludwig-Maximilians - University of Munich
NCT01858740 COMPLETED
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Fred Hutchinson Cancer Center
NCT04845035 WITHDRAWN
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
University of Michigan Rogel Cancer Center
NCT02435849 COMPLETED
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Novartis Pharmaceuticals
NCT03422679 TERMINATED
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
NCT05045443 COMPLETED
Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia
Ain Shams University
NCT04956666 COMPLETED
A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)
Institut de Recherches Internationales Servier
NCT05201183 WITHDRAWN
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Naoyuki G. Saito, M.D., Ph.D.
NCT03559413 COMPLETED
Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
University Children's Hospital Tuebingen
NCT02639559 COMPLETED
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
NCT02763384 TERMINATED
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Washington University School of Medicine
NCT03096782 COMPLETED
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT02065869 TERMINATED
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
NCT03733249 TERMINATED
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
NCT02661035 COMPLETED
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT01696461 COMPLETED
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Center for International Blood and Marrow Transplant Research
NCT01044745 TERMINATED
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
NCT05320380 WITHDRAWN
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Children's Oncology Group
NCT04224571 COMPLETED
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children
Chinese University of Hong Kong
NCT04029038 WITHDRAWN
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT03267186 COMPLETED
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Andrew Rezvani
NCT02311998 COMPLETED
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
M.D. Anderson Cancer Center
NCT04954326 COMPLETED
A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)
Institut de Recherches Internationales Servier
NCT01572662 COMPLETED
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
M.D. Anderson Cancer Center
NCT04562792 COMPLETED
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
Children's Mercy Hospital Kansas City
NCT02030847 COMPLETED
Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
University of Pennsylvania
NCT03705507 TERMINATED
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
University of Birmingham
NCT03389035 COMPLETED
Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
NCT02581007 COMPLETED
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT04067518 COMPLETED
A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
Institut de Recherches Internationales Servier
NCT01256398 COMPLETED
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT03109093 COMPLETED
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
Goethe University
NCT04323657 COMPLETED
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
NCT04156659 WITHDRAWN
Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
Novartis Pharmaceuticals
NCT00796068 COMPLETED
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Fred Hutchinson Cancer Center
NCT02743351 COMPLETED
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
NCT04225676 TERMINATED
Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals
NCT01028716 TERMINATED
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
NCT02593123 COMPLETED
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT02807883 COMPLETED
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT02412306 COMPLETED
Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen
NCT05571540 WITHDRAWN
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
Kunming Hope of Health Hospital
NCT03518112 TERMINATED
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT01842672 COMPLETED
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
New York Medical College
NCT01700946 COMPLETED
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
NCT04282174 WITHDRAWN
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Baptist Health South Florida
NCT03455140 COMPLETED
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
University of Birmingham
NCT01119066 COMPLETED
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
NCT03023046 COMPLETED
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
NCT00961142 TERMINATED
Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia
University Hospital Tuebingen
NCT01667133 COMPLETED
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Ariad Pharmaceuticals
NCT01865617 COMPLETED
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
NCT02043587 TERMINATED
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
University of California, San Diego
NCT00968864 TERMINATED
T-cell Depleted Alternative Donor Transplantation
Wake Forest University Health Sciences
NCT03668392 TERMINATED
Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT01685606 TERMINATED
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
Brown University
NCT04448834 WITHDRAWN
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
Dorothy Sipkins, MD, PhD
NCT04044560 TERMINATED
Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant
University of British Columbia
NCT03851081 WITHDRAWN
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
NCT01724879 COMPLETED
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
Goethe University
NCT01641107 COMPLETED
Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
Incyte Corporation
NCT02795520 TERMINATED
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
OncoTherapy Science, Inc.
NCT01620216 TERMINATED
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
NCT01523782 COMPLETED
Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia
ERYtech Pharma
NCT02067143 COMPLETED
MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT03742323 TERMINATED
REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia
PETHEMA Foundation
NCT01221857 COMPLETED
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Gamida Cell ltd
NCT01690520 COMPLETED
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Nohla Therapeutics, Inc.
NCT03602898 WITHDRAWN
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT01643408 COMPLETED
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Jazz Pharmaceuticals
NCT00860574 COMPLETED
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
NCT02500550 COMPLETED
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Kiadis Pharma
NCT01363128 COMPLETED
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT03094611 TERMINATED
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT01794299 COMPLETED
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Kiadis Pharma
NCT03076437 COMPLETED
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Institute for Innovation and Translational Medicine
NCT01338987 COMPLETED
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
National Cancer Institute (NCI)
NCT01025778 COMPLETED
Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia
Lund University Hospital
NCT01207440 COMPLETED
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Ariad Pharmaceuticals
NCT03289455 COMPLETED
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
Autolus Limited
NCT01930162 COMPLETED
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
Novartis Pharmaceuticals
NCT01474681 COMPLETED
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis Pharmaceuticals
NCT03739606 WITHDRAWN
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
City of Hope Medical Center
NCT02228096 COMPLETED
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Novartis Pharmaceuticals
NCT01258998 COMPLETED
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
NCT01914484 COMPLETED
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
University Health Network, Toronto
NCT01483690 TERMINATED
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
NCT01816230 COMPLETED
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell ltd
NCT00981799 TERMINATED
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Therapeutic Advances in Childhood Leukemia Consortium
NCT02991898 TERMINATED
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT03097770 COMPLETED
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Chinese PLA General Hospital
NCT02767934 TERMINATED
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
University of Washington
NCT01885897 COMPLETED
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Masonic Cancer Center, University of Minnesota
NCT00983528 TERMINATED
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
University of California, San Diego
NCT01528085 COMPLETED
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Goethe University
NCT01154816 COMPLETED
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Children's Oncology Group
NCT02333058 COMPLETED
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
medac GmbH
NCT02535364 TERMINATED
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)
Juno Therapeutics, a Subsidiary of Celgene
NCT00918333 COMPLETED
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
NCT01207388 COMPLETED
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
NCT00789776 COMPLETED
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT01527045 COMPLETED
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT02404220 TERMINATED
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Gilead Sciences
NCT00723099 COMPLETED
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT01326702 COMPLETED
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
NCT01251575 COMPLETED
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01012492 COMPLETED
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
Boston Children's Hospital
NCT01702155 COMPLETED
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
Delta-Fly Pharma, Inc.
NCT03195010 TERMINATED
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
NCT01529827 COMPLETED
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT02518113 COMPLETED
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
Eli Lilly and Company
NCT02535806 TERMINATED
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
NCT01839916 COMPLETED
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT01506453 COMPLETED
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
St. Jude Children's Research Hospital
NCT01159067 TERMINATED
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
NCT02518750 TERMINATED
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
NCT03187691 WITHDRAWN
Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia
Matinas BioPharma Nanotechnologies, Inc.
NCT01175785 COMPLETED
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Nohla Therapeutics, Inc.
NCT00968253 COMPLETED
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT01462253 COMPLETED
Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT03438344 WITHDRAWN
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT01769209 COMPLETED
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Stanford University
NCT02538926 WITHDRAWN
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
NCT01273766 COMPLETED
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Wake Forest University Health Sciences
NCT02632903 WITHDRAWN
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
Children's Hospital of Eastern Ontario
NCT00990249 COMPLETED
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
M.D. Anderson Cancer Center
NCT01745913 TERMINATED
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Weill Medical College of Cornell University
NCT01517035 COMPLETED
Improving Blood Stem Cell Collection and Transplant Procedures
National Heart, Lung, and Blood Institute (NHLBI)
NCT01050764 TERMINATED
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Everett Meyer
NCT02419469 TERMINATED
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT01162031 WITHDRAWN
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Stanford University
NCT01195480 TERMINATED
CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)
University College, London
NCT02269579 WITHDRAWN
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Jazz Pharmaceuticals
NCT01685021 TERMINATED
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
MorphoSys AG
NCT01491958 COMPLETED
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
NCT01564277 TERMINATED
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT00867529 COMPLETED
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Fred Hutchinson Cancer Center
NCT01312818 TERMINATED
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Masonic Cancer Center, University of Minnesota
NCT02765997 WITHDRAWN
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT01677949 WITHDRAWN
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Masonic Cancer Center, University of Minnesota
NCT01163201 WITHDRAWN
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
NCT02238925 COMPLETED
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Jazz Pharmaceuticals
NCT02544438 COMPLETED
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
BioSight Ltd.
NCT01466179 COMPLETED
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
NCT00702403 COMPLETED
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Fred Hutchinson Cancer Center
NCT01383447 TERMINATED
Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT00863148 COMPLETED
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
Nantes University Hospital
NCT01643668 COMPLETED
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT01167166 COMPLETED
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Traws Pharma, Inc.
NCT02259348 TERMINATED
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
St. Jude Children's Research Hospital
NCT00795769 COMPLETED
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01427881 COMPLETED
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT02200380 TERMINATED
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Celldex Therapeutics
NCT02227108 TERMINATED
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
MedImmune LLC
NCT02257684 TERMINATED
A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
Jazz Pharmaceuticals
NCT00973752 COMPLETED
Treatment of Older Adults With Acute Lymphoblastic Leukemia
Massachusetts General Hospital
NCT01209286 COMPLETED
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
NCT01621477 TERMINATED
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
NCT01475058 COMPLETED
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
Fred Hutchinson Cancer Center
NCT02167360 WITHDRAWN
Study of Efficacy and Safety of CTL019 in Adult ALL Patients
Abramson Cancer Center at Penn Medicine
NCT01471782 COMPLETED
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH
NCT00873093 COMPLETED
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Cancer Institute (NCI)
NCT01810120 COMPLETED
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT
Mariella Enoc
NCT02129062 TERMINATED
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT03005392 COMPLETED
Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
NCT01733953 COMPLETED
Statin Therapy in Young Adult Survivors of Childhood Cancer
University of Minnesota
NCT01401322 TERMINATED
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Stanford University
NCT01051154 COMPLETED
Effect of Enteral Docosahexaenoic Acid Administration in Children With Acute Lymphoblastic Leukemia
Coordinación de Investigación en Salud, Mexico
NCT02281279 WITHDRAWN
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Mayo Clinic
NCT01652014 WITHDRAWN
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
University of Medicine and Dentistry of New Jersey
NCT01297543 COMPLETED
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Cellerant Therapeutics
NCT01036009 COMPLETED
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
University of California, San Francisco
NCT00750659 COMPLETED
Nilotinib Pre and Post Allogeneic Stem Cell Transplantation
Sheba Medical Center
NCT00975975 COMPLETED
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Indiana University
NCT01413568 COMPLETED
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Polyphor Ltd.
NCT01795378 COMPLETED
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
Asan Medical Center
NCT00866281 TERMINATED
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
Novartis Pharmaceuticals
NCT01670084 WITHDRAWN
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Mayo Clinic
NCT02338050 TERMINATED
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
NCT02544789 COMPLETED
Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Betta Pharmaceuticals Co., Ltd.
NCT00905398 TERMINATED
Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Rony Schaffel
NCT01004497 COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
The Catholic University of Korea
NCT02150928 WITHDRAWN
An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Jazz Pharmaceuticals
NCT02373579 COMPLETED
Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia
Nancy Samir Elbarbary
NCT00560794 COMPLETED
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
NCT01500161 TERMINATED
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
NCT01095926 COMPLETED
Pharmacokinetic Study of Doxorubicin in Children With Cancer
University Hospital Muenster
NCT07585734 WITHDRAWN
Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT07572136 NOT YET RECRUITING
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
NCT07257419 RECRUITING
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
NCT07295951 RECRUITING
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Janssen Research & Development, LLC
NCT05397496 ACTIVE NOT RECRUITING
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis Pharmaceuticals
NCT05887167 RECRUITING
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Joshua Sasine, MD, PhD
NCT06777979 RECRUITING
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
NCT04872790 ACTIVE NOT RECRUITING
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
OHSU Knight Cancer Institute
NCT04771572 RECRUITING
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
NCT07565220 NOT YET RECRUITING
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
Sawa Ito, MD
NCT02879695 ACTIVE NOT RECRUITING
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT07556757 RECRUITING
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
ImmunityBio, Inc.
NCT06195891 RECRUITING
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT01044069 ACTIVE NOT RECRUITING
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
NCT05995028 RECRUITING
Universal 4SCAR7U Targeting CD7-positive Malignancies
Shenzhen Geno-Immune Medical Institute
NCT05707273 ACTIVE NOT RECRUITING
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission
City of Hope Medical Center
NCT07513129 NOT YET RECRUITING
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT05020678 ACTIVE NOT RECRUITING
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
NCT07539610 NOT YET RECRUITING
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
Institute of Hematology & Blood Diseases Hospital, China
NCT07532525 NOT YET RECRUITING
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
University of Michigan Rogel Cancer Center
NCT03853616 ACTIVE NOT RECRUITING
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
Miltenyi Biomedicine GmbH
NCT03132454 ACTIVE NOT RECRUITING
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
NCT04972942 RECRUITING
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
New York Medical College
NCT07166419 RECRUITING
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
NCT06047886 RECRUITING
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT05473910 RECRUITING
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics, Inc.
NCT07133997 RECRUITING
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
NCT06208735 RECRUITING
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
NCT04318678 RECRUITING
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
St. Jude Children's Research Hospital
NCT07020533 RECRUITING
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT07250087 RECRUITING
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
H. Lee Moffitt Cancer Center and Research Institute
NCT03533816 RECRUITING
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
University of Kansas Medical Center
NCT07491263 NOT YET RECRUITING
Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
Fujian Medical University
NCT05292664 RECRUITING
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Andrew E. Place, MD
NCT05535855 RECRUITING
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
University of Colorado, Denver
NCT05679895 RECRUITING
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
OneChain Immunotherapeutics
NCT06326008 RECRUITING
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
Beijing GoBroad Hospital
NCT05581030 RECRUITING
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
H. Lee Moffitt Cancer Center and Research Institute
NCT05157971 RECRUITING
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
NCT06575296 RECRUITING
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
City of Hope Medical Center
NCT07220993 RECRUITING
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Baylor College of Medicine
NCT07078929 RECRUITING
Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)
Chulalongkorn University
NCT06173518 RECRUITING
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
NCT03802695 RECRUITING
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
NCT06863259 RECRUITING
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Children's Hospital Medical Center, Cincinnati
NCT06227026 RECRUITING
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
University of Utah
NCT04690595 ACTIVE NOT RECRUITING
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
PeproMene Bio, Inc.
NCT06408194 RECRUITING
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
NCT06287528 RECRUITING
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Memorial Sloan Kettering Cancer Center
NCT00586391 ACTIVE NOT RECRUITING
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Baylor College of Medicine
NCT05044039 ACTIVE NOT RECRUITING
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Washington University School of Medicine
NCT03666000 RECRUITING
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
NCT06326463 RECRUITING
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
NCT07361029 RECRUITING
CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia
King Faisal Specialist Hospital & Research Center
NCT03571321 RECRUITING
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
University of Chicago
NCT04872478 RECRUITING
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Meryx, Inc.
NCT01853631 RECRUITING
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Baylor College of Medicine
NCT06934382 RECRUITING
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Stephan Grupp MD PhD
NCT07300683 RECRUITING
Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma
University College, London
NCT04881240 RECRUITING
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
St. Jude Children's Research Hospital
NCT06447987 RECRUITING
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
NCT07284927 RECRUITING
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
NCT07280494 RECRUITING
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
Peking University People's Hospital
NCT03560752 ACTIVE NOT RECRUITING
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT02146924 ACTIVE NOT RECRUITING
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
City of Hope Medical Center
NCT02091245 ACTIVE NOT RECRUITING
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Dana-Farber Cancer Institute
NCT06080191 RECRUITING
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
Bambino Gesù Hospital and Research Institute
NCT06559189 RECRUITING
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
University of Colorado, Denver
NCT07246707 RECRUITING
KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Zhejiang University
NCT06507514 RECRUITING
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
The First Affiliated Hospital of Soochow University
NCT03740334 ACTIVE NOT RECRUITING
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
Dana-Farber Cancer Institute
NCT07239323 RECRUITING
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Chongqing Precision Biotech Co., Ltd
NCT07234045 NOT YET RECRUITING
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
NCT03233854 ACTIVE NOT RECRUITING
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Stanford University
NCT02050347 ACTIVE NOT RECRUITING
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Baylor College of Medicine
NCT03326921 RECRUITING
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT04260022 RECRUITING
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
NCT03595917 RECRUITING
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Marlise Luskin, MD
NCT03690011 RECRUITING
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Baylor College of Medicine
NCT02508038 RECRUITING
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT03620058 ACTIVE NOT RECRUITING
CART22 Alone or in Combination With huCART19 for ALL
University of Pennsylvania
NCT04606433 ACTIVE NOT RECRUITING
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05705570 RECRUITING
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
Nelson Hamerschlak
NCT02159495 ACTIVE NOT RECRUITING
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
City of Hope Medical Center
NCT03081910 RECRUITING
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Baylor College of Medicine
NCT07113496 NOT YET RECRUITING
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
NCT07106749 RECRUITING
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
NCT06287944 RECRUITING
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
NCT07066397 RECRUITING
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
TriArm Therapeutics (Taiwan) Limited
NCT01494103 ACTIVE NOT RECRUITING
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Baylor College of Medicine
NCT00710892 ACTIVE NOT RECRUITING
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Baylor College of Medicine
NCT05857969 RECRUITING
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
NCT00840853 ACTIVE NOT RECRUITING
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Baylor College of Medicine
NCT05139004 ACTIVE NOT RECRUITING
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT04732845 ACTIVE NOT RECRUITING
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Benjamin Tomlinson
NCT02494882 ACTIVE NOT RECRUITING
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Memorial Sloan Kettering Cancer Center
NCT03774654 ACTIVE NOT RECRUITING
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
NCT07043218 NOT YET RECRUITING
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Tongji Hospital, Tongji University School of Medicine
NCT03241940 ACTIVE NOT RECRUITING
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
NCT07040982 NOT YET RECRUITING
Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
City of Hope Medical Center
NCT01430390 ACTIVE NOT RECRUITING
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Memorial Sloan Kettering Cancer Center
NCT01860937 ACTIVE NOT RECRUITING
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT06927466 RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
NCT05418088 RECRUITING
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Sumithira Vasu
NCT06462365 RECRUITING
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
NCT06879340 RECRUITING
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
University of Kansas Medical Center
NCT02443831 RECRUITING
CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
University College, London
NCT04088864 ACTIVE NOT RECRUITING
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford University
NCT06894693 NOT YET RECRUITING
A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies
Guangdong Ruishun Biotech Co., Ltd
NCT06060782 RECRUITING
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
Fifth Affiliated Hospital, Sun Yat-Sen University
NCT05054257 RECRUITING
CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Institute of Hematology and Blood Transfusion, Czech Republic
NCT06752785 RECRUITING
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Guangzhou Women and Children's Medical Center
NCT05476770 RECRUITING
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT06034275 RECRUITING
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.
NCT06641024 NOT YET RECRUITING
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
Chongqing Precision Biotech Co., Ltd
NCT06593145 RECRUITING
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
FamiCordTx
NCT05333302 RECRUITING
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
NCT06136364 RECRUITING
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Hebei Senlang Biotechnology Inc., Ltd.
NCT06056752 RECRUITING
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Anhui Provincial Hospital
NCT03962465 ACTIVE NOT RECRUITING
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
University of Virginia
NCT05210907 RECRUITING
Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Seoul National University Hospital
NCT04214886 ACTIVE NOT RECRUITING
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
Loyola University
NCT04595162 NOT YET RECRUITING
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Peking University Third Hospital
NCT07586618 NOT YET RECRUITING
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Allterum Therapeutics, Inc
NCT06649006 COMPLETED
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Amgen
NCT07498465 WITHDRAWN
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
Children's Oncology Group
NCT02315612 COMPLETED
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT04996160 COMPLETED
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Tanja Andrea Gruber
NCT02333162 SUSPENDED
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
University of Chicago
NCT04088890 COMPLETED
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Matthew Frank
NCT03494569 SUSPENDED
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT05170828 WITHDRAWN
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
NCT05350787 COMPLETED
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL
Zhejiang University
NCT05694364 COMPLETED
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT04681105 COMPLETED
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
NCT04139434 COMPLETED
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Newave Pharmaceutical Inc
NCT04049383 TERMINATED
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
Medical College of Wisconsin
NCT01139970 COMPLETED
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
National Cancer Institute (NCI)
NCT05400122 SUSPENDED
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
David Wald
NCT02996773 COMPLETED
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
NCT02879643 COMPLETED
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
Therapeutic Advances in Childhood Leukemia Consortium
NCT04984356 COMPLETED
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Wugen, Inc.
NCT06027957 COMPLETED
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Vinmec Research Institute of Stem Cell and Gene Technology
NCT05153330 TERMINATED
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
NCT05521087 WITHDRAWN
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
NCT02446964 COMPLETED
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
NCT05290155 COMPLETED
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT03448393 COMPLETED
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT02303821 COMPLETED
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
NCT02975687 COMPLETED
CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT05292898 TERMINATED
A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT03472573 COMPLETED
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03286114 TERMINATED
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
University of Michigan Rogel Cancer Center
NCT05038644 TERMINATED
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
Ehab L Atallah
NCT03755414 COMPLETED
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT00588991 COMPLETED
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
National Cancer Institute (NCI)
NCT04537715 COMPLETED
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Epizyme, Inc.
NCT03751709 COMPLETED
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Cedars-Sinai Medical Center
NCT01743807 TERMINATED
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
NCT05775406 COMPLETED
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
Kymera Therapeutics, Inc.
NCT04526795 TERMINATED
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
NCT05032599 TERMINATED
Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Beijing Boren Hospital
NCT05487495 WITHDRAWN
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
NCT03884829 TERMINATED
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Cyclacel Pharmaceuticals, Inc.
NCT05326516 COMPLETED
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
Syndax Pharmaceuticals
NCT01523977 COMPLETED
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
Dana-Farber Cancer Institute
NCT03198234 TERMINATED
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
Roncarolo, Maria Grazia, MD
NCT05564819 COMPLETED
Efficacy and Safety of Acetaminophen in Postoperative Pain Management of Infants
Nanjing Children's Hospital
NCT03103971 TERMINATED
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
NCT04524455 COMPLETED
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
Amgen
NCT01588015 COMPLETED
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT01684150 COMPLETED
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
Epizyme, Inc.
NCT02081378 COMPLETED
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis Pharmaceuticals
NCT04557436 COMPLETED
TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)
Great Ormond Street Hospital for Children NHS Foundation Trust
NCT03878524 TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
NCT03964259 COMPLETED
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
Virginia Commonwealth University
NCT02168140 COMPLETED
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Wake Forest University Health Sciences
NCT03919526 COMPLETED
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT05321940 WITHDRAWN
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Juan C. Ramos, MD
NCT00697684 COMPLETED
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Beth Israel Deaconess Medical Center
NCT01523223 COMPLETED
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Robert Lowsky
NCT05961696 WITHDRAWN
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT02122081 COMPLETED
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Sumithira Vasu
NCT05519527 WITHDRAWN
STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
M.D. Anderson Cancer Center
NCT03991884 COMPLETED
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
University of Washington
NCT01029366 COMPLETED
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
University of Pennsylvania
NCT02588456 TERMINATED
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
University of Pennsylvania
NCT05037669 WITHDRAWN
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
University of Pennsylvania
NCT02141828 COMPLETED
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Epizyme, Inc.
NCT03236857 COMPLETED
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
AbbVie
NCT01925131 COMPLETED
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
SWOG Cancer Research Network
NCT02185781 COMPLETED
Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT04230473 COMPLETED
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
NCT05513612 WITHDRAWN
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
NCT02890758 COMPLETED
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Brenda Cooper, MD
NCT01756118 COMPLETED
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Goethe University
NCT02960646 COMPLETED
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
NCT05168748 WITHDRAWN
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
NCT05563545 COMPLETED
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
Shanghai Simnova Biotechnology Co.,Ltd.
NCT03349281 COMPLETED
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
Julio Barredo, MD
NCT02706392 TERMINATED
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
NCT03768310 WITHDRAWN
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
Baylor College of Medicine
NCT02529813 COMPLETED
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT03483324 COMPLETED
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
Angiocrine Bioscience
NCT04844086 TERMINATED
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
Eden BioCell Ltd.
NCT01187810 TERMINATED
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
South Plains Oncology Consortium
NCT04888468 COMPLETED
Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Chongqing Precision Biotech Co., Ltd
NCT02293109 COMPLETED
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
Mehrdad Abedi, MD
NCT03696537 TERMINATED
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Naoyuki G. Saito, M.D., Ph.D.
NCT02730312 COMPLETED
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Xencor, Inc.
NCT02083250 COMPLETED
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03519984 TERMINATED
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
University of Southern California
NCT03263637 COMPLETED
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
AstraZeneca
NCT03181126 COMPLETED
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
AbbVie
NCT02808442 COMPLETED
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
Institut de Recherches Internationales Servier
NCT02746952 COMPLETED
Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia
Institut de Recherches Internationales Servier
NCT02374333 COMPLETED
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
University of Pennsylvania
NCT03555955 COMPLETED
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Jazz Pharmaceuticals
NCT04572308 COMPLETED
Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells
Hebei Senlang Biotechnology Inc., Ltd.
NCT04082286 COMPLETED
Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia
Great Ormond Street Hospital for Children NHS Foundation Trust
NCT01822509 COMPLETED
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
NCT03885947 COMPLETED
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Alla Keyzner
NCT02669264 TERMINATED
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
ADC Therapeutics S.A.
NCT02129582 COMPLETED
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT00866307 COMPLETED
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
Children's Oncology Group
NCT02341963 TERMINATED
A Pilot Clinical Trial of Oral Ketamine for Acute Pain Management After Amputation Surgery
Rush University Medical Center
NCT01713582 COMPLETED
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT01077544 COMPLETED
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals
NCT01300611 TERMINATED
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
Tarix Pharmaceuticals
NCT01943682 COMPLETED
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
NCT04094766 WITHDRAWN
Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
NCT02750254 TERMINATED
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT03515200 TERMINATED
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
NCT01593696 COMPLETED
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
National Cancer Institute (NCI)
NCT00674427 TERMINATED
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
University of Pennsylvania
NCT03807063 WITHDRAWN
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01159028 COMPLETED
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
Bio-Path Holdings, Inc.
NCT02779283 COMPLETED
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
NCT02212561 COMPLETED
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
NCT02588092 TERMINATED
Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
ADC Therapeutics S.A.
NCT02819804 TERMINATED
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Northwestern University
NCT01887587 TERMINATED
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
Ehab L Atallah
NCT02231853 TERMINATED
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
National Heart, Lung, and Blood Institute (NHLBI)
NCT01300572 COMPLETED
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
Fred Hutchinson Cancer Center
NCT02228772 COMPLETED
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Massachusetts General Hospital
NCT01408160 TERMINATED
Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Albert Einstein College of Medicine
NCT01216332 COMPLETED
Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients
Vanderbilt University
NCT01974479 SUSPENDED
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
National University Health System, Singapore
NCT00928200 TERMINATED
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Therapeutic Advances in Childhood Leukemia Consortium
NCT02086773 COMPLETED
Red Cell Transfusion Goals in Patients With Acute Leukemias
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01634217 COMPLETED
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
NCT03414450 WITHDRAWN
Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
NCT02728700 TERMINATED
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
NCT01319864 COMPLETED
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Seattle Children's Hospital
NCT01484015 COMPLETED
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
NCT02226861 COMPLETED
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
National Heart, Lung, and Blood Institute (NHLBI)
NCT01910428 TERMINATED
L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL
ERYtech Pharma
NCT02168907 TERMINATED
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Wake Forest University Health Sciences
NCT01567709 COMPLETED
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
NCT02578511 WITHDRAWN
Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Ehab L Atallah
NCT02815059 WITHDRAWN
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
University of Utah
NCT00854646 COMPLETED
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Traws Pharma, Inc.
NCT01207076 TERMINATED
AHN-12 Biodistribution in Advanced Leukemia
Masonic Cancer Center, University of Minnesota
NCT00686556 COMPLETED
Total Marrow Irradiation for Refractory Acute Leukemia
Masonic Cancer Center, University of Minnesota
NCT01110473 COMPLETED
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
AbbVie (prior sponsor, Abbott)
NCT00659425 COMPLETED
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
NCT00988715 COMPLETED
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT01169012 COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
UNC Lineberger Comprehensive Cancer Center
NCT01324180 COMPLETED
Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)
H. Lee Moffitt Cancer Center and Research Institute
NCT02647190 WITHDRAWN
Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Memorial Sloan Kettering Cancer Center
NCT02071927 COMPLETED
Study of the Glutaminase Inhibitor CB-839 in Leukemia
Calithera Biosciences, Inc
NCT02861040 WITHDRAWN
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Northwestern University
NCT01527838 COMPLETED
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
Fate Therapeutics
NCT00891592 COMPLETED
Umbilical Cord Blood Transplant for Hematological Malignancies
University of Pennsylvania
NCT01204164 COMPLETED
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Tragara Pharmaceuticals, Inc.
NCT01075425 COMPLETED
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
NCT01049113 TERMINATED
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Traws Pharma, Inc.
NCT00860535 TERMINATED
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
Merck Sharp & Dohme LLC
NCT02109224 TERMINATED
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
National Cancer Institute (NCI)
NCT01403415 COMPLETED
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT00608361 COMPLETED
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00963495 TERMINATED
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
University Health Network, Toronto
NCT00990587 COMPLETED
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
University Health Network, Toronto
NCT01149915 COMPLETED
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Threshold Pharmaceuticals
NCT01088763 TERMINATED
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
NCT00964873 COMPLETED
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Synta Pharmaceuticals Corp.
NCT01132573 COMPLETED
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
National Cancer Institute (NCI)
NCT00933985 TERMINATED
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
NCT01231919 COMPLETED
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
NCT00940524 COMPLETED
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT01655875 TERMINATED
AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia
Emory University
NCT01196013 COMPLETED
A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia
Genzyme, a Sanofi Company
NCT00890747 COMPLETED
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
NCT01068301 COMPLETED
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
St. Jude Children's Research Hospital
NCT00911066 COMPLETED
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Millennium Pharmaceuticals, Inc.
NCT00957320 WITHDRAWN
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
Emory University
NCT01697020 COMPLETED
Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions
Nova Laboratories Limited
NCT00807677 COMPLETED
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Millennium Pharmaceuticals, Inc.
NCT01066468 TERMINATED
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
Novartis Pharmaceuticals
NCT06289673 RECRUITING
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
NCT06035757 RECRUITING
The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
Konkuk University Medical Center
NCT07320534 NOT YET RECRUITING
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
Gadjah Mada University
NCT07016165 RECRUITING
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Gadjah Mada University
NCT06918054 RECRUITING
Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia
Ain Shams University
NCT06918080 ACTIVE NOT RECRUITING
Hepatoprotective Measures for Children at High Risk of NAFLD
Ain Shams University
NCT06711679 ENROLLING BY INVITATION
Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia
Yilin Zhao
NCT06410833 RECRUITING
Belimumab After Rituximab in Resistant Primary Juvenile SS
Peking Union Medical College Hospital
NCT05682131 RECRUITING
South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05687032 COMPLETED
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer
NCT04506086 TERMINATED
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
NCT04846855 COMPLETED
Regional Anesthesia for Totally Awake Upper Limb Surgery in PEDiatric Population
Ramsay Générale de Santé
NCT01735955 COMPLETED
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis Pharmaceuticals
NCT03677596 COMPLETED
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Pfizer
NCT03043430 TERMINATED
Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients
Brooke Army Medical Center
NCT03318393 COMPLETED
Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO
University of Texas Southwestern Medical Center
NCT02024230 COMPLETED
Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)
Fujita Health University
NCT02618109 TERMINATED
Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia
University Hospital, Angers
NCT02447718 COMPLETED
Vaccinating Children After Chemotherapy
Canadian Immunization Research Network
NCT05176119 COMPLETED
Nalbuphine Versus Ketamine for Prevention of Emergence Agitation After Sevoflurane in Children Undergoing Tonsillectomy
Ain Shams University
NCT03369847 COMPLETED
Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge
New York City Health and Hospitals Corporation
NCT02060175 WITHDRAWN
Comparison of the 3-month Strut Coverage After Coronary Stenting by Optical Coherence Tomography; Cilotax and DESyne
Yonsei University
NCT01358253 COMPLETED
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Ruijin Hospital
NCT01472302 COMPLETED
Closed Loop Ventilation Strategy in Intensive Care Unit (ICU) Patients
Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital
Full ALL Pipeline
Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only